spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  postmenopausal osteoporosis 

 HSMN NewsFeed - 8 Jun 2018
European Commission Approves Prolia(R) (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 27 Apr 2018
Amgen Receives Positive CHMP Opinion To Expand Use Of Prolia(R) (denosumab) To Patients With Glucocorticoid-Induced Osteoporosis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 28 Apr 2017
FDA Approves Radius Health’s TYMLOS(TM) (abaloparatide), a Bone Building Agent for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Feb 2016
Amgen And UCB Announce Positive Top-Line Results From The Phase 3 Study Of Romosozumab In Postmenopausal Women With Osteoporosis
Biopharmaceuticals
 HSMN NewsFeed - 13 Aug 2014
Tarsa Therapeutics Secures $10 Million And Adds Industry Veteran Daniel Soland As A Director
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 3 Oct 2013
Pfizer Inc. Announces FDA Approval of DUAVEE(TM) (conjugated estrogens/ bazedoxifene) for the Treatment of Moderate-to-Severe Vasomotor Symptoms (Hot Flashes) Associated with Menopause and the Prevention of Postmenopausal Osteoporosis [1]
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Feb 2013
Amgen Outlines Long-Term Strategy
Biopharmaceuticals
 HSMN NewsFeed - 19 Sep 2011
FDA Approves New Indications for Prolia(R) (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Nov 2010
Unigene Names Alex Martin VP Business Development and Head of Commercial Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Oct 2010
Warner Chilcott Announces FDA Approval of Next Generation Actonel
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Jul 2010
Tarsa Therapeutics Advances Phase III ORACAL Trial of its Oral Calcitonin for the Treatment of Postmenopausal Osteoporosis
Biopharmaceuticals
 HSMN NewsFeed - 9 Jun 2010
Unigene Appoints New CEO, Ashleigh Palmer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Jun 2010
FDA Approves Amgen's Prolia(TM) (Denosumab) for Treatment of Postmenopausal Women With Osteoporosis at High Risk for Fracture
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 May 2010
Prolia(R) (Denosumab) Granted Marketing Authorization in the European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 20 Feb 2010
FDA Classifies Prolia(TM) (Denosumab) Complete Response Submission and Targets Action Date
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 Oct 2009
Amgen Provides Update on Status of Prolia(TM) (Denosumab) Biologics License Application (BLA) Submitted to the U.S. Food and Drug Administration (FDA)
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Sep 2009
Wyeth Presents Data from Five-Year Vertebral Fracture Prevention Study with Bazedoxifene
Biopharmaceuticals
 HSMN NewsFeed - 14 Sep 2009
Lilly Names New Business Leaders
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Jul 2009
Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)
Biopharmaceuticals
 HSMN NewsFeed - 9 Jun 2009
Par Pharmaceutical Begins Shipment of Generic Miacalcin(R)
Biopharmaceuticals Generics
 HSMN NewsFeed - 1 Jun 2009
FDA Approves Reclast(R) to Prevent Osteoporosis in Postmenopausal Women With Convenient Less Frequent Dosing
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Apr 2009
Ligand Announces Approval in Europe of CONBRIZA for Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 19 Dec 2008
Amgen Submits Biologics License Application for FDA Approval of Denosumab in Women With Postmenopausal Osteoporosis and in Patients Undergoing Hormone Ablation for Either Prostate or Breast Cancer
Biopharmaceuticals
 HSMN NewsFeed - 8 Dec 2008
First Head-To-Head Study Shows That Protelos(R) (Strontium Ranelate) Builds Better Bone Than Bisphosphonate
Biopharmaceuticals
 HSMN NewsFeed - 15 Sep 2008
Denosumab Osteoporosis Trial Finds Patients Transitioned from Alendronate (Fosamax(R)) to Denosumab Achieved Significantly Greater Gains in Bone Mineral Density versus Those Continuing on Alendronate
Biopharmaceuticals
 HSMN NewsFeed - 25 Jul 2008
Amgen Announces Positive Top-Line Results for Denosumab Pivotal Postmenopausal Osteoporosis Trial
Biopharmaceuticals
 HSMN NewsFeed - 5 Jun 2008
FDA Broadens US Indication for Once-Yearly Reclast(R) as Only Osteoporosis Treatment Approved for Prevention of Fractures After a Hip Fracture
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 May 2008
Denosumab Achieved Superior Bone Mineral Density Gains in Head-to-Head Trial versus Weekly Alendronate (FOSAMAX(R))
Biopharmaceuticals
 HSMN NewsFeed - 23 May 2008
Wyeth Receives Approvable Letter From FDA for Bazedoxifene for the Treatment of Postmenopausal Osteoporosis
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Apr 2008
Pivotal Phase 3 Data Show Denosumab Increased Bone Density at Multiple Skeletal Sites in Early and Later Stage Postmenopausal Women
Biopharmaceuticals
 HSMN NewsFeed - 24 Jan 2008
Denosumab Osteoporosis Study Met Primary and All Secondary Bone Mineral Density Endpoints in a Head-to-Head Comparison with Weekly Alendronate (FOSAMAX(R))
Biopharmaceuticals
 HSMN NewsFeed - 24 Dec 2007
Wyeth Receives Approvable Letter from FDA for Bazedoxifene for the Prevention of Postmenopausal Osteoporosis
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Dec 2007
Pivotal Phase 3 Data Show Denosumab Increased Bone Density Throughout Skeleton in Non-Metastatic Breast Cancer Patients on Adjuvant Aromatase Inhibitor Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Sep 2007
New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
Biopharmaceuticals
 HSMN NewsFeed - 19 Sep 2007
Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
Biopharmaceuticals
 HSMN NewsFeed - 18 Sep 2007
First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
Biopharmaceuticals
 HSMN NewsFeed - 18 Aug 2007
Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 May 2007
Once-yearly Reclast(R) Significantly Reduced Bone Fractures in Women with Postmenopausal Osteoporosis
Biopharmaceuticals Orthopaedic
 HSMN NewsFeed - 24 Apr 2007
Wyeth Receives Approvable Letter from FDA for Bazedoxifene for the Prevention of Postmenopausal Osteoporosis
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Apr 2007
Wyeth Responds to Special Report Published in New England Journal of Medicine
 HSMN NewsFeed - 17 Apr 2007
Reclast(R) Receives US Approval as a Highly Effective Treatment for Patients with Paget's Disease of the Bone
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Feb 2007
Initiation of Phase III Program Using Emisphere's eligen(R) Technology for Oral Salmon Calcitonin
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 30 Jan 2007
Agreement between Ipsen and MSD for the Co-Marketing in France of Adrovance(TM) for the Treatment of Postmenopausal Osteoporosis
Biopharmaceuticals Licensing
 HSMN NewsFeed - 4 Dec 2006
Nastech Pharmaceutical Company Inc. Provides Update on Parathyroid Hormone (PTH1-34) Nasal Spray for Treatment of Osteoporosis
Biopharmaceuticals
 HSMN NewsFeed - 17 Sep 2006
Women More Likely to Stay on Once-Monthly Boniva(R) Versus Once-Weekly Osteoporosis Medicines
Biopharmaceuticals
 HSMN NewsFeed - 16 Sep 2006
Once-Yearly Reclast(R)* Demonstrates Highly Significant Fracture Risk Reductions in the Treatment of Postmenopausal Osteoporosis, New Study Shows
Biopharmaceuticals
 HSMN NewsFeed - 26 Jun 2006
Wyeth Submits Two New Drug Applications for Women's Health Therapies
Biopharmaceuticals
 HSMN NewsFeed - 10 May 2006
Unigene Enters into Exclusive Distribution Agreement for Fortical(R) Nasal Spray in Israel
Biopharmaceuticals Drug Delivery Distribution
 HSMN NewsFeed - 8 May 2006
Wyeth Comments on New Report From The Nurses' Health Study Published Today in the Archives of Internal Medicine
Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 46

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 46 additional stories matching:
postmenopausal osteoporosis
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!